A nomogram for predicting T315I-free survival in chronic phase chronic myeloid leukemia patients: a multicenter retrospective study

The T315I mutation poses a significant threat to patients with chronic phase chronic myeloid leukemia (CP-CML). This study aimed to establish a nomogram to predict the risk of T315I mutation in CP-CML patients. The training cohort included 1,466 patients from 24 hematology centers, and the validation cohort included 820 patients from an additional 20 centers. Peripheral blood blast (PBB), additional chromosomal abnormality (ACA), dasatinib use, non-EMR at 3 months, and BCR::ABL<sup>IS</sup> > 1% at 6 months were identified as independent risk factors through multivariate Cox regression analysis. The performance of the nomogram was assessed via receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). The area under the ROC curve (AUC) values at 5, 10, and 15 years were 0.874, 0.925, and 0.930 for the training cohort, and 0.864, 0.814, and 0.803 for the validation cohort, respectively. The calibration curves for both cohorts were close to the ideal diagonal, and the decision curves indicated clinical net benefit. In conclusion, we developed a nomogram to predict the 5-year, 10-year, and 15-year T315I-free survival probabilities of CP-CML patients. This tool can aid clinicians in the early prediction and timely management of high-risk CP-CML patients with the T315I mutation.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2025-02-18
DOI
https://doi.org/10.1038/s41598-025-89851-y
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A nomogram for predicting T315I-free survival in chronic phase chronic myeloid leukemia patients: a multicenter retrospective study

Jie Jin, Weiying Feng, Kaifeng Zhang, Guoli Yao et al.
Scientific Reports
Chronic Myeloid Leukemia Treatments
article

A nomogram for predicting T315I-free survival in chronic phase chronic myeloid leukemia patients: a multicenter retrospective study

Jie Jin, Weiying Feng, Kaifeng Zhang, Guoli Yao, Shiwei Hu, Jing Le, Dijiong Wu, Hongyan Tong, Xiaoning Feng, Jingjing Zhu, Yue‐Feng Zhang, Yongqing Jia, Gang Zhang, Xiaoqiong Zhu, Ying Lü, Yongming Xia, Lili Chen, Yi Wang, Yú Chen, Li Zhang, Xiujie Zhou, Feng Zhu, Honglan Qian, Hui Zhou, Lirong Liu, Lihong Cao, Jian Huang, Lixin Huang, Huiqi Zhang, Linjuan Xu, Xiudi Yang, Yanping Shao, Guoyan Tian, Xiufeng Yin, Gongqiang Wu, Jinming Tu
article en

Abstract

The T315I mutation poses a significant threat to patients with chronic phase chronic myeloid leukemia (CP-CML). This study aimed to establish a nomogram to predict the risk of T315I mutation in CP-CML patients. The training cohort included 1,466 patients from 24 hematology centers, and the validation cohort included 820 patients from an additional 20 centers. Peripheral blood blast (PBB), additional chromosomal abnormality (ACA), dasatinib use, non-EMR at 3 months, and BCR::ABL<sup>IS</sup> > 1% at 6 months were identified as independent risk factors through multivariate Cox regression analysis. The performance of the nomogram was assessed via receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). The area under the ROC curve (AUC) values at 5, 10, and 15 years were 0.874, 0.925, and 0.930 for the training cohort, and 0.864, 0.814, and 0.803 for the validation cohort, respectively. The calibration curves for both cohorts were close to the ideal diagonal, and the decision curves indicated clinical net benefit. In conclusion, we developed a nomogram to predict the 5-year, 10-year, and 15-year T315I-free survival probabilities of CP-CML patients. This tool can aid clinicians in the early prediction and timely management of high-risk CP-CML patients with the T315I mutation.

Scientific ReportsVol. 15(1)
Ningbo University (CN), Zhejiang Chinese Medical University (CN), Wenzhou Medical University (CN), First Affiliated Hospital of Wenzhou Medical University (CN), Sir Run Run Shaw Hospital (CN), Lishui University (CN), Jiaxing University (CN), Tongde Hospital of Zhejiang Province (CN), Affiliated Hospital of Hangzhou Normal University (CN), Ningbo Medical Center Lihuili Hospital (CN), Zhoushan Hospital (CN), Lishui City People's Hospital (CN), Jiyang College of Zhejiang A&F University (CN), Zhejiang Shuren University (CN), Zhejiang Academy of Medical Sciences (CN), First Hospital of Jiaxing (CN), Taizhou First People's Hospital (CN), Third People's Hospital of Huzhou (CN), First People's Hospital of Nanning (CN), Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine (CN), Dongyang People's Hospital (CN), Shaoxing People's Hospital (CN), Zhejiang Medicine (China) (CN), Yuxian People's Hospital (CN), First Affiliated Hospital Zhejiang University (CN), Zhejiang University (CN)
Zhejiang Medical Association
Good health and well-being
Openalex Percentile: Top 96%
Chronic Myeloid Leukemia Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.